- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01704846
Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules
Assessment of Bioequivalence Between Two Different Formulations of BI 201335 NA Soft Gelatine Capsules in Healthy Male Volunteers. (an Open-label, Randomised, Single-dose, Four-period Replicated Crossover Study)
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Sumida-ku,Tokyo, Japan
- 1220.53.08101 Boehringer Ingelheim Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion criteria:
- Healthy male volunteers without any clinical significant findings and complications
- Age: 20 - 45 years
- BMI: 18.5 - 25.0 kg/m2
- Signed informed consent
Exclusion criteria:
- Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance.
- Any evidence of a clinically relevant concomitant disease according to investigator's clinical judgement.
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
- History of jaundice
- Surgery of the gastrointestinal tract (except appendectomy).
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.
- History of relevant orthostatic hypotension, fainting spells or blackouts.
- Chronic or relevant acute infections.
- History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) according to investigator's clinical judgement.
- Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- Use of drugs which might reasonably influence the results (pharmacokinetic) of the trial within at least 10 days prior to administration or during the trial.
- Participation in another trial with an investigational drug within two months prior to administration or during the trial.
- Smoking (>10 cigarettes or >3 cigars or >3 pipes/day).
- Inability to refrain from smoking during the trial.
- Alcohol abuse (more than 60 g/day: e.g., 3 middle-sized bottles of beer, 3 gous [equivalent to 540 mL] of sake).
- Drug abuse.
- Blood donation (more than 100 mL within four weeks prior to administration).
- Excessive physical activities (within one week prior to administration).
- Any laboratory value outside the reference range that is of clinical relevance according to investigator's clinical judgement.
- Any history of relevant liver diseases (for instance, disturbances of liver function, Dubin-Johnson syndrome, Rotor syndrome, or previous liver tumours).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Treatment sequence 1
Test - Reference - Reference - Test
|
1capsule of BI 201335 NA 120 mg capsule
1 capsule of BI 201335 NA 120 mg capsule
3 capsules of BI 201335 NA 40 mg capsule
|
Eksperimentell: Treatment sequence 2
Reference - Test - Test - Reference
|
1capsule of BI 201335 NA 120 mg capsule
1 capsule of BI 201335 NA 120 mg capsule
3 capsules of BI 201335 NA 40 mg capsule
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Area Under the Curve of the Analyte From Time 0 to the Last Quantifiable Data Point (AUC0-tz)
Tidsramme: 3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Area under the concentration-time curve of the faldaprevir in plasma over the time interval from 0 to the time of the last quantifiable data point. Geometric means presented are adjusted means and the coefficient of variation is the intra-individual geometric coefficient of variation. |
3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Maximum Measured Concentration (Cmax)
Tidsramme: 3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Maximum measured concentration of faldaprevir in plasma.
Geometric means presented are adjusted means and the coefficient of variation is the intra-individual geometric coefficient of variation.
|
3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Area Under the Curve Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)
Tidsramme: 3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Area under the concentration-time curve of faldaprevir in plasma over the time interval from 0 extrapolated to infinity. Geometric means presented are adjusted means and the coefficient of variation is the intra-individual geometric coefficient of variation. |
3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Time From Dosing to the Maximum Measured Concentration (Tmax)
Tidsramme: 3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Time from dosing to the maximum measured concentration of the analyte in plasma. Means presented are adjusted means and the standard deviation is actually the intra-individual coefficient of variation. |
3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Terminal Rate Constant (λz)
Tidsramme: 3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Terminal rate constant of the analyte in plasma.
Geometric means presented are adjusted means and the coefficient of variation is the intra-individual geometric coefficient of variation.
|
3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Terminal Half-life (t1/2)
Tidsramme: 3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Terminal half-life of faldaprevir in plasma.
Geometric means presented are adjusted means and the coefficient of variation is the intra-individual geometric coefficient of variation.
|
3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Mean Residence Time (MRTpo)
Tidsramme: 3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Mean residence time of the analyte in the body after oral administration.
Geometric means presented are adjusted means and the coefficient of variation is the intra-individual geometric coefficient of variation.
|
3 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and 96h after drug administration
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 1220.53
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hepatitt C
-
Dokuz Eylul UniversityEge UniversityFullførtMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CTyrkia
-
Tripep ABInovio PharmaceuticalsUkjentKronisk hepatitt C virusinfeksjonSverige
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsTilbaketrukketKronisk hepatitt C virusinfeksjonIsrael
-
Hadassah Medical OrganizationUkjentKronisk hepatitt C virusinfeksjonIsrael
-
Johann Wolfgang Goethe University HospitalFullført
-
Beni-Suef UniversityFullførtٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin og HCV genotype 4-infiserte egyptisk erfarne deltakereKronisk hepatitt C virusinfeksjonEgypt
-
University College CorkDupont Applied BiosciencesRekruttering
-
Trek Therapeutics, PBCFullførtKronisk hepatitt C | Hepatitt C genotype 1 | Hepatitt C (HCV) | Hepatitt C viral infeksjonForente stater, New Zealand
-
Trek Therapeutics, PBCFullførtKronisk hepatitt C | Hepatitt C (HCV) | Hepatitt C genotype 4 | Hepatitt C viral infeksjonForente stater
-
Meir Medical CenterFullførtUtvikle ny teknikk for å måle C/D-forhold fra digitale stereooptiske plater | Intraobserver reproduserbarhet av C/D-målinger | Interobservatørvariabilitet av C/D-målinger
Kliniske studier på BI 201335 NA 120 mg capsule
-
Boehringer IngelheimFullførtHepatitt C, kroniskForente stater, Argentina, Australia, Østerrike, Canada, Tsjekkisk Republikk, Frankrike, Tyskland, Korea, Republikken, Nederland, Portugal, Romania, Spania, Sveits, Storbritannia
-
Boehringer IngelheimFullført
-
Boehringer IngelheimFullført
-
Boehringer IngelheimFullført
-
Boehringer IngelheimFullført
-
Boehringer IngelheimFullført
-
Boehringer IngelheimFullført
-
Boehringer IngelheimFullført
-
Boehringer IngelheimFullført
-
Boehringer IngelheimAvsluttet